Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Ferris RL, et al. Among authors: saba nf. J Clin Oncol. 2022 Jan 10;40(2):138-149. doi: 10.1200/JCO.21.01752. Epub 2021 Oct 26. J Clin Oncol. 2022. PMID: 34699271 Free PMC article. Clinical Trial.
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.
McDonald MW, Lawson J, Garg MK, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ; Expert Panel on Radiation Oncology-Head and Neck Cancer. McDonald MW, et al. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1292-8. doi: 10.1016/j.ijrobp.2011.02.014. Epub 2011 Apr 27. Int J Radiat Oncol Biol Phys. 2011. PMID: 21530100 Review.
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Ramalingam SS, et al. Among authors: saba nf. J Thorac Oncol. 2013 Mar;8(3):369-72. doi: 10.1097/JTO.0b013e318282709c. J Thorac Oncol. 2013. PMID: 23407561 Free PMC article. Clinical Trial.
ACR Appropriateness Criteria® thyroid carcinoma.
Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. Salama JK, et al. Oral Oncol. 2014 Jun;50(6):577-86. doi: 10.1016/j.oraloncology.2013.12.004. Oral Oncol. 2014. PMID: 24824115
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. Galloway TJ, et al. Among authors: saba nf. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8. Clin Cancer Res. 2015. PMID: 25573383 Free PMC article. Clinical Trial.
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. Gilbert J, et al. Oral Oncol. 2015 Apr;51(4):376-82. doi: 10.1016/j.oraloncology.2014.12.011. Epub 2015 Jan 13. Oral Oncol. 2015. PMID: 25593015 Free PMC article. Clinical Trial.
307 results